Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Sintetol and Tetanus Vaccine in Healthy Subjects
NCT06607380Phase 1Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Atorva in Tetanus (3 arms), sponsored by Trinomab Pharmaceutical. Primary endpoints: Maximum concentration at Day 106, Area Under the Curve from time 0 to last quantifiable time point at Day 106 and 2 more. Started Aug 2022; status: completed.
02
Drugs
Atorva
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06607380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607380.